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Globally, a large number of blockbuster biotherapeutic molecules are going off patent in the next few
years. For emerging economies, like India, it is imperative to be able to provide safe and cost effective
drugs for its huge, non-insured and poor population. India has a robust pharmaceutical industry
including the biopharmaceutical sector which is actively engaged in the production and marketing of
‘non-innovator’ or ‘copy’ biotherapeutic products These products are approved through an abbreviated
route which relies on limited safety and efﬁcacy data enabling the local companies to keep the
production costs low and pass on the price beneﬁt to the patient and make the product affordable to the
masses. Some of the available products may not be truly ‘similar’ and may be of suspect quality. The WHO
[1] and the European Medicines Agency (EMA) [2] have published guidelines for the development and
marketing of biosimilar products. These products, as stated in both guidelines undergo extensive head-
to-head comparability testing with the reference biotherapeutic product (RBP) to show their similarity to
the RBP in terms of quality, efﬁcacy and safety. Regulators and administrators of different countries need
to strike a balance in cost-to-beneﬁt versus risks that are perceived for these products, keeping in mind
global regulatory issues.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
India is the 2nd most populous country in the world with
a population of approximately 1.2 billion. Only a small minority of
the population of the country is insured or has the economic
capability to afford standard-of-care medical care especially high-
end, expensive biotherapeutic products. Mass affordability is
a genuine problem in India and other developing countries.
Because of this pressure, the regulatory process reﬂects a complex
interplay between economics, science, public health and politics.
In terms of volume, India is the world’s 2nd largest supplier of
vaccines and 4th largest supplier of pharmaceuticals. The country
also has a robust biopharma sector with over 100 companies
actively engaged in development or production of copy bio-
therapeutic products. The emphasis of the Indian biopharma
industry had been directed more toward development of ‘copies’
rather than original molecules because of much lower develop-
mental costs and risks, reduced spending on research and devel-
opment, reduced time to market and expertise in reverse262 2899/510 5589.
ll rights reserved. The World Healthengineering drug development process. Over 50 different brands of
copy products are approved for more than 20 different bio-
pharmaceutical companies and some of these molecules have
completed a decade of market presence with several thousand
doses already administered. Even though there have been some
concerns and questions that all locally manufactured products are
not truly biosimilars, their acceptance by, both, the prescribers and
the patients has been good [3,4].
Strict guidelines have been laid down by the Indian Regulatory
bodies for the approval of Indian non-innovator/copy products.
These have been published and are available on the website of the
Central Drug Standard Control Organization and the Schedule Y of
the Drug and Cosmetic Rules. These are based on the recommen-
dations of a Task force on recombinant-pharmaceuticals accepted
by the government of India in January 2006 [5].
The Indian guidelines for the approval process of non-
innovator/copy products [6] are to some extent different from
the EMA and the recently published WHO guidelines. In the
present review, an attempt will be made to provide the present
status of the non-innovator biotherapeutic industry in India and
the regulatory processes governing the approval of the same. The
difference between the WHO and the Indian guidelines will be
highlighted.Organization has granted the Publisher permission for the reproduction of this article.
Table 1B
Non-innovator biotherapeutic products under development in India.
Product Type Application
Peg IFN-a Cytokine Hepatitis, certain
hematological cancers
IFN-b Cytokine Multiple Sclerosis
Etanercept TNF Fusion protein Rheumatoid arthritis
(RA) and other joint
disorders, Psoriasis
Inﬂiximab Monoclonal antibody
against TNF (Chimeric)
Inﬂammatory bowel
disease, RA & autoimmune
joint disorders
Trastuzumab
(Herceptin)
Monoclonal antibody
against HER2
(humanized)
HER2 expressing
breast cancers
Bevacizumab
(Avastin)
Monoclonal antibody
against VEGF
(humanized)
Colorectal, breast,
non-small cell
lung cancers,
Age related macular
degeneration
Luteinizing
Hormone
Hormone Used in gonadotropin
deﬁciency states
Human Menopausal
Gonadotropin (HMG)
Hormone Induction of ovulation
Palvizumab (Synagis) Monoclonal antibody
directed against
respiratory syncytial
virus (RSV) (humanized)
Used in children
at high risk of
RSV infection.
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The opportunity for marketing non-innovator products in India
is huge e approximately 50 biologicals patented prior to 1995 are
now marketable in the country. To exploit this demand several
home-grown biopharma industries are now actively developing
and marketing non-innovator products in India.
The intensity of competition can be gauged from Table 1. Pres-
ently, there are 16 brands of Erythropoietin (EPO) and 14 brands of
granulocyte colony stimulating factor (G-CSF) available in the
Indianmarket and new ones are being added every fewmonths [4].
There have been concerns regarding the quality of available
molecules and questions whether these copy products are at all
‘similar’ to the innovator products. Another major concern in India
and other developing countries has been the maintenance of the
cold chain at the stockist level and the viability of the product when
it reaches the consumer.
Global market for Indian non-innovator products was anticipated
to be approximately USD 1.5 billion in 2006 with a compounded
annual growth rate of 27%. It is estimated that the exports of Indian
biopharma products are increasing at the rate of 47% (2008) [4].
Availability of non-innovator products provides major price
advantages to the patients as innovators sometimes drop prices by
30e50%, sometimes 2e3 years ahead of launch of the biosimilar
product. As a generalization, prices of non-innovator products are
approximately 45e75% of the price of the innovator product [4].
In India, there has been good acceptance of non-innovator
products amongst health care professionals and patients. For
example of the total sales of G-GCF, 65% is comprised of non-
innovator products by volume and for EPO, these non-innovator
products account for 40% of total annual sales [4].
The Indian regulators are attempting to ensure a high quality of
the products. The recently published and released (August 2010)
6th Edition of the Indian Pharmacopoeia includes product-speciﬁc
monographs for 5 biological drug substances including insulin,
interferon, EPO, G-CSF and streptokinase andmonographs for other
biologic products are under development [7].
3. Indian regulatory process for non-innovator
biotherapeutic products
The Indian regulatory system for non-innovator products is
a stand-alone system and is followed for all the biotechnology-
derived products since 1996 [5,6]. There are several departmentsTable 1A
Non-innovator biotherapeutic products marketed in India.
Product Launched
(no. of COs)
Pursuing
(no. of COs)
G-CSF 14 20
EPO 16 20
Peg EPO 1 2
Peg G-CSF 2 7
Alpha-IFN 06 12
IL-2 1 2
FSH 1 3
PTH 1 5
HGH 2 8
Rituximab (anti-CD20 monoclonal antibody) 1 5
HCG 1 4
Streptokinase 2 2
TPA 1 1
EGRFI Mab 1 2
CO: Company, G-CSF: Granulocyte Colony Stimulating Factor, EPO: Erythropoietin,
Peg: Pegylated, IFN: Interferon, IL-2: Interleukin-2, FSH: Follicle Stimulating
Hormone, PTH: Parathyroid hormone, HGH: Human Growth Hormone, HCG:
Human chorionic gonadotrophine, TPA: Tissue Thromboplastin activator, EGFRI
Mab: Epidermal Growth Factor Inhibitor Monoclonal antibody.and committtees involved (Table 2). The regulations for non-
innovator products are different from the published WHO and
the EMA guidelines (Table 3). The approval requirements for any
new non-innovator product are shown in Fig. 1. These comprise
physico-chemical and biological characterization, non-clinical
toxicity studies and Phase III conﬁrmatory clinical trials. None of
the assessment includes any comparative testing at all.
The regulatory process has deﬁned protocols for 5 scenarios for
which committee clearances are mandatory. For example, products
without Live Micro-organisms (LMO) could be:
1. Indigenous product Development, Manufacturing & Marketing
(RCGM & DCGI)
2. Import and Marketing (DCGI)
Products with LMO are evaluated under the following heads:
1. Indigenous product Development, Manufacturing & Marketing
(RCGM, GEAC & DCGI)
2. Import and Marketing (GEAC, DCGI)
3. Import of bulk, for Manufacturing & Marketing (RCGM, GEAC,
DCGI)Table 2
Indian Regulatory Authorities involved in the approval of biotherapeutic products.
Committee Department Responsibility
Review Committee
for Genetic
Manipulation
(RCGM)
Department of
Biotechnology e
Ministry of Science &
Technology
Monitors all researchescale
activity and approval for
non-clinical studies
Genetic
Engineering
Advisory
Committee
(GEAC)
Ministry of Environment Environmental safety for
large-scale operations of Live
Modiﬁed Organism (LMO)
based products
Drug Controller
General of India
(DCGI)
Ministry of Health Product safety and efﬁcacy &
Clinical Trial & Marketing
approval for Biotech drugs
Food & Drugs
Control
Administration
(FDCA)
State government body,
UnderMinistry of Health
Approves plant & ensures
cGMP.
Table 3
Key differences between the guidelines published by the WHO and the existing
Indian regulatory system for approval of non-innovator biological products.
Area Indian Regulatory Expectation WHO/EMEA
Process  GMP certiﬁed facility.
 Full cell bank characterization
as per ICH guideline.
 Post approval changes warrant
comparability study (as per ICH
Q5E and Post Approval
guideline published by DCGI,
India).
 Extractable studies are needed.
 Viral validation study is not
mandatory.
 GMP certiﬁed facility.
 Full cell bank characterization as
per ICH guideline.
 Post approval changes warrants
comparability study (as per ICH
Q5E and Post approval guideline
published by DCGI, India).
 Extractable studies are needed.
 Viral validation study is
mandatory.
Analytical  Detailed characterization is
expected (including the Post
translational modiﬁcation).
 Speciﬁcation needed to be
justiﬁed.
 CMC requirement as per DCGI
guideline (in line with ICH M4).
 Detailed characterization is
mandatory.
 Speciﬁcation needed to be
justiﬁed.
 CMC requirement is as per ICH
M4.
Clinical  Comparative PK/PD is not
mandatory.
 Comparative CT is not
mandatory.
 Scientiﬁc advice process is
not in place.
 Exploration to other indication
can be obtained.
 PMS is mandatory for 4 years
with every 6 months safety
reporting (PSUR) for ﬁrst 2 year.
 Immunogenicity is not
mandatory, but expected.
 Comparative PK/PD is required.
 Comparative CT is required.
 Scientiﬁc advice process is in
place for EMA, not for all WHO
countries.
 Exploration to other indication
can only be approved if the
clinical MOA is similar.
 PMS is mandatory.
 Immunogenicity is mandatory.
[EMEA e European Medicines Agency; GMP e Good Manufacturing Practices; ICH e
International Committee on Harmonization; DCGI e Drug Controller General of
India; CMC e Central Monitoring Committee; PK/PD e PharmacoKinetics/Pharmaco
Dynamics; CT e Clinical Trial; PMS e Post Marketing Surveillance; PSUR e Periodic
Safety Update Report].
Table 4
Dossier Requirements for submission of new biological product.
Information Details
Basic pharmaceutical
information
- Name, dosage form, composition, container
closure.
- Classiﬁcation, indication, patent status.
Clone related information - Details of GMO (Gene, Vector and Host).
- Cloning details.
- Biosafety measures & risk management.
Product characterization Physico-chemical & biological
characterization of the product (Structure,
biological activity and impurities)
Process e Drug Substance
(DS) & Drug Product (DP)
- Manufacturing procedure including
parameters.
- In-process controls in the process.
- Rawmaterials and processingmaterial testing.
- Equipment, machinery & facility.
- Consistency of process, process validation.
Quality Control and Quality
Assurance
- Speciﬁcation of DS and DP.
- Method of analysis of DS and DP.
Stability of DS & DP
Pre approval regulatory
inspections
- All GMP matters.
- Review of all the quality systems.
- Review of manufacturing facility (DS, DP & QC)
& utilities.
- Review of documents submitted in the dossier.
- Process validation, analytical method
validation.
- Cell Bank characterization, stability.
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The Indian regulatory authorities have speciﬁed the dossier
requirements for submission for approvals of non-innovator
biotherapeutic products [6]. The dossier needs to haveFig. 1. Summary of the regulatory pathway for approval of non-innovator biotherapeutics
CT e Clinical Trial; GMP e Good Manufacturing Practices; DSMD e Data Safety & Mo
PV e Pharmaco Vigilance; PSUR e Periodic Safety Update Report].considerable information; relevant details are provided in Table 4
and below:
3.1.1. Non-clinical studies
These need to assess single dose toxicity (dose tolerance), repeat
dose toxicity (also with recovery period), local tolerance and
allergenicity and have to be done in at least two relevant species
with route of administration resembling clinics (IV/IM/SC) andwith
control animals in each study (vehicle control) [6].
These studies can be non-comparative and comparative study is
not a regulatory requirement but some large companies are per-
forming comparisons.in India. [GLP e Good Laboratory Practices; DCGI e Drug Controller General of India;
nitoring Board; CTD e Clinical Trials Dossier; PMS e Post Marketing Surveillance;
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A conﬁrmatory Phase III Clinical Trial to evaluate safety and
efﬁcacy is mandatory before approval. The trial should be multi-
centre but can be single-arm, open label and non-comparative with
the originator molecule.
Standard Inclusion and Exclusion criteria and the clinical trials
protocol has to be approved by the DCG(I) & Institutional Ethics
committee. The clinical trial needs to adhere to Good Clinical
Practices with evaluation of adequate clinical parameters with
statistical evaluation. Post marketing studies are also required by
the authorities.
4. Summary & conclusions
With more and more innovator/RBP going off patent, urgent
attention is required to regulate the increasing number of copy
biotherapeutics. New non-innovator biotherapeutics should be
made available as soon as patent protection is over so that the
economically compromised patients who cannot afford the high
cost of the originator molecule have an option to opt for the
cheaper copy versions. Reducing the cost of drugs is now a global
priority rather than just being a major issue in developing econo-
mies [8]. Biopharma industry in many developing countries is
ready and capable of manufacturing world-class non-innovator
biotherapeutic products. However, it is imperative that the local
regulatory authorities ensure that the manufacturer maintains the
quality and consistency of the ﬁnished product across batches over
time [9]. This can be a major challenge especially in developing
countries [10,11].
The costs associated with conducting comparative clinical trials
should not be so high that the new manufacturer is unable to
perform the trial or passes on the cost of the trial to the patient
making the non-innovator product out of economic reach for the
majority of patients. Efﬁcacy and safety of non-innovator products
should be ensured by the national regulatory authorities.
Developing speciﬁc guidelines is important for approval of copy
biotherapeutics in India. Like guidelines for vaccines, product-
speciﬁc guidelines for biosimilar products are needed. Theseshould include various aspects e.g. quality of the product, phar-
maco vigilance, cold chain maintenance etc.
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